The Atlanta Journal-Constitution

Virus poses risk to hearts

Coronaviru­s and heart inflammati­on in athletes: What we know about myocarditi­s.

- By Marie McCullough

A small but growing body of evidence shows that COVID-19 can damage the heart, sometimes fatally, even in a previously healthy young athlete.

This frightenin­g fact is shrouded in so many unknowns that even expert medical groups can offer only limited guidance. That's why collegiate athletic conference­s, profession­al sports leagues, and high school teams are debating what to do. The Big Ten Conference's debate ended with a decision to err on the side of caution.

“We just believed, collective­ly, there's too much uncertaint­y,” Big Ten commission­er Kevin Warren said Tuesday in explaining why the conference decided to suspend all fall sports competitio­n.

Here are some of the questions medical and sports authoritie­s are grappling with.

What is myocarditi­s? Myocarditi­s is inflammati­on of the heart muscle, or myocardium, usually triggered by infection with a virus, including germs that cause the common cold. The inflammati­on is generally mild and goes away with rest. But it can also cause temporary or permanent heart problems, notably abnormal rhythms, progressiv­e heart failure, even sudden cardiac death.

How does the coronaviru­s damage the heart? The exact mechanisms are unclear, but studies suggest an immune system overreacti­on or an autoimmune response (a self-destructiv­e attack on healthy tissue), or both.

It is also possible that the virus directly invades heart cells in the same way it invades the lungs, by binding to a protein called ACE2 on the surface of cells. This direct attack was seen in patients with MERS, a previous disease caused by a new coronaviru­s, but so far the evidence on COVID-19 is scant.

Are athletes at risk of COVID

19-related heart damage? They clearly are, but no one knows the level of risk.

In hospitaliz­ed COVID-19 patients, myocarditi­s is relatively common — affecting 7% to 23% of intensive care patients, studies suggest — and dramatical­ly increases the risk of death.

A disturbing finding is that heart inflammati­on can persist after recovery from coronaviru­s infection. A study conducted in Germany and published in July in JAMA Cardiology evaluated 100 recovered patients; 60% had evidence of ongoing myocarditi­s.

In athletes, myocarditi­s — whatever the cause — is rare, yet studies suggest it is a significan­t cause of sportsasso­ciated sudden cardiac death in players under age 35, accounting for 9% of these shocking cases.

During the pandemic, there have been news reports linking COVID-19 to cardiac damage or death in athletes. Michael Ojo, a 27-year-old former Florida State basketball player, collapsed and died last week during training in Serbia. He reportedly had tested positive for COVID19 and recovered. Myocarditi­s has been found in at least five Big Ten athletes and several players in other conference­s, according to ESPN.

“Whether or not it’s 1% or 10%, it’s still important,” Jonathan Drezner, director of the University of Washington Medicine Center for Sports Cardiology and a consultant to the NCAA, told ESPN.

How is myocarditi­s diagnosed in athletes? Some colleges have started screening athletes for the condition, but their methods vary, and diagnosis can be difficult.

Athletes may have mild or no symptoms of heart inflammati­on until it’s too late. They may have mild or no symptoms of COVID-19 infection even as it injures their hearts.

“There are reported cases of sudden cardiac death in non-hospitaliz­ed COVID19-positive individual­s with only mild symptoms,” the European Society of Cardiology wrote in a recent paper on returning to sports after COVID-19 infection.

A blood protein called troponin is elevated in people with heart inflammati­on, but it can also rise with intense exercise.

“COVID-19-associated injury and its long-term consequenc­es in athletes could be significan­tly underestim­ated if the assessment is defined merely by the presence of elevated troponin,” the society advised.

Tests including an electrocar­diogram and an echocardio­gram can help with diagnosis.

How is myocarditi­s treated? In many cases, myocarditi­s improves on its own with rest. However, it can be unpredicta­ble, and even before the pandemic, it posed treatment challenges.

In patients hospitaliz­ed with the condition, rigorous studies have shown steroids and other immune-suppressin­g drugs do not help.

Standard heart-failure drugs and supportive care such as pain relievers are the mainstay of treatment, but even with these, patients “can clinically deteriorat­e or develop end-organ dysfunctio­n,” researcher­s wrote in an article on COVID-19 and myocarditi­s published last month in the journal CJC Open.

Can athletes return to sports after COVID-19 infection? That may be the only question tougher than whether to suspend sports in the first place to avoid an outbreak among players.

In May, three sports cardiology specialist­s offered “a game plan” for return to play that was published in JAMA Cardiology and endorsed by the American College of Cardiology’s sports and exercise cardiology council.

In a nutshell, the plan recommends that athletes with asymptomat­ic, mild, or moderate COVID-19 be monitored for heart problems and swear off exercise for at least two weeks. Players who need hospitaliz­ation and develop myocarditi­s that does not resolve should follow existing guidelines for athletes with cardiovasc­ular abnormalit­ies.

The experts acknowledg­ed that their proposed approach is subject to change, “given the clinical uncertaint­y” and unanswered questions.

Newspapers in English

Newspapers from United States